Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)
China · Delayed Price · Currency is CNY 29.36
-0.24 (-0.81%)
At close: Jan 21, 2026
SHA:688443 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
Operating Revenue | 225.14 | 30.07 | 1.07 | 0.48 | - | - | Upgrade |
Other Revenue | 0.03 | 0.03 | 0.15 | - | 39.19 | 1.09 | Upgrade |
| 225.16 | 30.09 | 1.21 | 0.48 | 39.19 | 1.09 | Upgrade | |
Revenue Growth (YoY) | 1560.46% | 2384.11% | 154.92% | -98.79% | 3502.99% | 3393.88% | Upgrade |
Cost of Revenue | 15.86 | 5.92 | -0.24 | 1.77 | 19.67 | 0.71 | Upgrade |
Gross Profit | 209.3 | 24.17 | 1.45 | -1.3 | 19.52 | 0.38 | Upgrade |
Selling, General & Admin | 307.63 | 252.49 | 173.79 | 153.62 | 24.22 | 114.53 | Upgrade |
Research & Development | 521.22 | 609.79 | 620.4 | 454.49 | 295.32 | 235.86 | Upgrade |
Other Operating Expenses | 8.44 | 3.27 | 2.56 | 1.3 | 1.84 | 1.29 | Upgrade |
Operating Expenses | 837.81 | 866.19 | 796.74 | 609.42 | 321.34 | 351.72 | Upgrade |
Operating Income | -628.51 | -842.02 | -795.29 | -610.72 | -301.82 | -351.34 | Upgrade |
Interest Expense | -31.28 | -28.9 | -34.99 | -32.75 | -32.42 | -34.41 | Upgrade |
Interest & Investment Income | 38.62 | 66.75 | 17.46 | 0.88 | 0.43 | 0.32 | Upgrade |
Currency Exchange Gain (Loss) | - | - | -0.1 | -0.8 | 0.24 | 0.57 | Upgrade |
Other Non Operating Income (Expenses) | 0.57 | -0.02 | -0.02 | -0.01 | -0.02 | -0.01 | Upgrade |
EBT Excluding Unusual Items | -620.6 | -804.18 | -812.94 | -643.39 | -333.59 | -384.88 | Upgrade |
Gain (Loss) on Sale of Investments | 5.01 | 2.58 | 1.94 | 7.14 | 4.11 | 0.36 | Upgrade |
Gain (Loss) on Sale of Assets | -5.39 | -0.54 | -0 | -0 | - | 0 | Upgrade |
Asset Writedown | -0.28 | - | - | - | -0.43 | -1.93 | Upgrade |
Other Unusual Items | 37.74 | 4.86 | 9.68 | 59.89 | 7.78 | 13.83 | Upgrade |
Pretax Income | -583.52 | -797.27 | -801.32 | -576.37 | -322.13 | -372.62 | Upgrade |
Net Income | -583.52 | -797.27 | -801.32 | -576.37 | -322.13 | -372.62 | Upgrade |
Net Income to Common | -583.52 | -797.27 | -801.32 | -576.37 | -322.13 | -372.62 | Upgrade |
Shares Outstanding (Basic) | 367 | 367 | 321 | 274 | 275 | - | Upgrade |
Shares Outstanding (Diluted) | 367 | 367 | 321 | 274 | 275 | - | Upgrade |
Shares Change (YoY) | 0.03% | 14.63% | 16.79% | -0.32% | - | - | Upgrade |
EPS (Basic) | -1.59 | -2.17 | -2.50 | -2.10 | -1.17 | - | Upgrade |
EPS (Diluted) | -1.59 | -2.17 | -2.50 | -2.10 | -1.17 | - | Upgrade |
Free Cash Flow | -480.03 | -620.75 | -468.56 | -323.85 | -350.52 | -196.8 | Upgrade |
Free Cash Flow Per Share | -1.31 | -1.69 | -1.46 | -1.18 | -1.27 | - | Upgrade |
Gross Margin | 92.95% | 80.32% | 119.44% | -273.11% | 49.80% | 34.77% | Upgrade |
Operating Margin | -279.14% | -2797.87% | -65645.33% | -128506.77% | -770.14% | -32301.05% | Upgrade |
Profit Margin | -259.16% | -2649.19% | -66142.68% | -121278.86% | -821.97% | -34256.70% | Upgrade |
Free Cash Flow Margin | -213.19% | -2062.65% | -38675.98% | -68143.75% | -894.41% | -18092.66% | Upgrade |
EBITDA | -568.67 | -786.89 | -746.46 | -570.86 | -270.57 | -320.06 | Upgrade |
D&A For EBITDA | 59.84 | 55.12 | 48.84 | 39.86 | 31.26 | 31.28 | Upgrade |
EBIT | -628.51 | -842.02 | -795.29 | -610.72 | -301.82 | -351.34 | Upgrade |
Revenue as Reported | 225.16 | 30.09 | 1.21 | 0.48 | 39.19 | 1.09 | Upgrade |
Advertising Expenses | - | 2.34 | 0.35 | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.